Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan-Reference-Cited by-同舟云学术

Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan

Published:2023-12 Issue: Volume:15 Page:100390
ISSN:2590-1362
Container-title:Vaccine: X
language:en
Short-container-title:Vaccine: X

Author:

Sonoyama Takuhiro,Kamitani Akari,Shibata Risa Y.,Seki Naomi M.,Omoto Shinya,Igarashi Kenji,Ariyasu Mari

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference17 articles.

1. World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int Last accessed: July 18, 2022.

2. Waning antibody responses in asymptomatic and symptomatic SARS-CoV-2 infection;Choe;Emerg Infect Dis,2021

3. Centres for Disease Control and Prevention. COVID-19 Risks and Vaccine Information for Older Adults. Available from: https://www.cdc.gov/aging/covid19/index.html Last accessed: September 25, 2023.

4. The vaccine efficacy against the Sars-Cov-2 Omicron: A systemic review and meta-analysis;Zou;Front Public Health,2022

5. UK Health Security Agency. COVID-19 vaccine surveillance report Week 16. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1070356/Vaccine-surveillance-report-week-16.pdf Last accessed: September 30, 2022.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults;Scientific Reports;2024-04-29